PDE4A and chronic obstructive pulmonary disease: The reason for a lack of clinical effectiveness of these highly potent and long lived inhaled PDE4 inhibitors might be a result of the presence of other PDE subtypes within the lung (e.g., PDE2, 3, 7) that might contribute to airway inflammation in COPD.